Exchange: NASDAQ·Updated 05:22 PM EDT
AYTU logo

AYTU Aytu BioPharma Inc

$1.99
$0.025
(1.22%)
Today
Closed $2.03
$0.0387
(1.91%)
After Hours
Mkt Cap$22.28M
Vol10,528.00

About AYTU

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Denver, CO.
42

Bearish Sentiment

How do you feel about AYTU?

biid
$AYTU This company's story has changed since the acquisition of EXXUA. It is very likely the best-in-class drug in Major Depressive Disorder (MDD) -- which has a $22.0B US market -- with no sexual or weight gain side-effects. The company's legacy portfolio's sales remain robust and allow the company to focus on EXXUA sales, which keep going up quarter-to-quarter. Exciting times for the company as it grows and finally provides real shareholder value.
5
KuntaKinteh
$AYTU Diahbrow, I’ve heard U goin’ down, biatch!!! Am hearing Feds & handcuffs, also American Greed! Hair Paint Company that becomes Pharmaceutical ti deceive investors, over half a bln $, investors money, outa capital to present some lies!!! What a Trash CEO, Criminal At Tops!!!
5
Henry20feb_
$AYTU AYTU’s FY26 numbers look weak on the surface, but Q4 tells a very different story. Revenue rebounded to $16.1M, EXXUA jumped from $2.4M to $3.9M QoQ with prescriptions up 138%, and adjusted EBITDA returned positive at $0.5M, while cash remains solid at $26.3M. The legacy ADHD business is still declining YoY, but if EXXUA continues anywhere near its current trajectory, its first full commercial year could clearly outperform the ~$10M probability-weighted forecast — Q4 may well mark the turning point.
4
Skipper_Jack
$AYTU What kind of company is this? "Oh they are different now" Nope... this is the real aytu. Dilution and RS that follows.
3
DOC1977
$AYTU I’ve been here for the past two r/s and I have about 1000 shares left and need about 40 bucks to break even and after all this time we r still sitting at 2 bucks so mabe for the next r/s how about we all vote against it , so to me there is nothing to b bullish about just my opinion from a very long shareholder
3
Telorino
$AYTU I’m left wandering why JD hasn’t gone the AI route… He could’ve at least tried through their Aytu RX platform; made some sh.t up… Try to pump it one last time; give some bag holders a chance to try to get some pennies on the dollar… But, nope! Not even that, that worthless pos of a CEO! The BOD is complicit as well; they all haver earned at least some FBI time… Naaaa! The whole system’s rigged!
3
Skipper_Jack
$AYTU JD will soon be dusting off his favorite dance move - fake news into offering/dilution, followed by RS. He's the best!! I remembered when he diluted well below the selling price killing a rally. That was fun. It's was almost like he didn't want the price to go up... hmmm. Maybe that is why he settled the class action If you buy this crap company, you deserve to lose your money
1
Skipper_Jack
$AYTU Be on the look out for JD staring next season on American Greed.. the episode will be called, "The Covid Lie - The missing test kits"
1
Telorino
$AYTU POS results! Almost a full year of Exxua and it doesn’t sell… Worse off, they tried to pump it at the expense of the rest of the portfolio! Lost money again on the whole!!! R/S coming sooner rather than later!
1
biid
$AYTU If this keeps going lower, I will buy more. These are bargain prices. EXXUA revenue will overtake legacy revenue in about a couple quarters (three max). It doesn't matter what bears say; you can't argue with top line and bottom line. We might suffer a bit while there's no news (and thus limited volume and interest) but I believe we'll be in a great place a couple quarters from now. I've done my DD and love what I see here. They literally somehow fleeced Fabre-Kramer for the best-in-class drug in MDD and are going to grow it to the moon. If they grow EXXUA by 50% a quarter (a fair / potentially conservative estimate), they'll make ~$47.5M in EXXUA alone in the next fiscal year.
Carlosdimarcodiaguano
$AYTU real positive signals here this stock might actually be worth something. Watching for now

Advertisement|Remove ads.